CNS Pharmaceuticals Inc is providing hope to those who suffer from one of the deadliest forms of cancer proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
Study to evaluate efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer
Interim analysis of trial when 50% of planned subjects reach 6 months in study
Sublicensee, WPD Pharmaceuticals to initiate a Phase 2 multicenter clinical trial in Poland of Berubicin in GBM in the second half of 2021; Interim analysis of the first 18 adult patients expected in first half of 2022
News provided by
Share this article
(NASDAQ: CNSP) ( CNS or the Company ), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.
Markets
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Reata Pharmaceuticals (RETA – Research Report) on April 26. The company’s shares closed last Wednesday at $103.79.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 15.9% and a 49.6% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Reata Pharmaceuticals with a $186.33 average price target, implying an 82.4% upside from current levels. In a report issued on April 26, Barclays also initiated coverage with a Buy rating on the stock with a $155.00 price target.
Share:
WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the
Company or
WPD ) a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10
th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021.
During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: New approach to glioblastoma treatment addressing the critical unmet medical need , granted by National Research and Development Center (
NRDC ) and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020.
CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021
Potentially pivotal study evaluating efficacy of Berubicin in the treatment of adult Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer
News provided by
Share this article
(NASDAQ: CNSP) ( CNS or the Company ), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today indicated that the clinical program for Berubicin is on track to start enrolling patients in March 2021. CNS lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of a number of serious brain and CNS oncology indications.